Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 17 of 17 for “"Apremilast"”.
-
Comparison of the modes of action of Apremilast and Roflumilast
… investigated for use as therapeutic agents. Apremilast, a small molecule inhibitor of PDE 4 is in development for chronic inflammatory disorders and has shown promise for the treatment of psoriasis, psoriatic arthritis as well as other inflammatory diseases. It has been found to be safe and …
-
Development of an amorphous based novel sustained release system for apremilast
As a small molecule PDE 4 inhibitor, apremilast has drawn much attention for multiple promising indications. However, apremilast is a poorly water-soluble drug and has multiple polymorphic forms. This study aims to develop a sustained-release (SR) amorphous solid dispersion (ASD) system for …
-
cAMP-abhängige Signalkomplexe bei Pemphigus vulgaris
… Mit der Zulassung des Phosphodiesterasehemmers Apremilast steht mittlerweile ein klinisch zugelassenes Medikament zu Verfügung, das, neben den in der Zulassungsstudie beschriebenen Effekten auf das Immunsystem, auch den cAMP-Spiegel in Keratinozyten erhöht. Im Herzmuskel wurde von einer Stärkung …
-
Μελέτη πολυμορφισμών ανοσορυθμιστικών κυτοκινών σε ασθενείς με ψωρίαση και άλλες δερματολογικές παθήσεις
… associated with treatment response to apremilast and secukinumab and evaluate their predictive value in therapeutic outcomes. Specifically, this study aims to investigate the impact of genetic polymorphisms on psoriasis patients treated with apremilast or secukinumab while …
-
Chemokine orchestration of leukocyte-skin interactions
… in patients treated with the PDE4 inhibitor Apremilast. Strikingly, Apremilast treatment of neutrophils led to the abolishment of intracellular calcium fluxes, known to be related to reduced neutrophil migration. Further to this, we show that Apremilast treatment of mice with psoriasiform …
-
Η επίδραση της θεραπείας με αναστολείς της ιντερλευκίνης 17 και ιντερλευκίνης 23 στην αθηρωματική νόσο σε ασθενείς με μέτρια ή σοβαρή ψωρίαση κατά πλάκας
… IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the …
-
Novel approaches for ungual and trans-ungual delivery of drugs
… project was to investigate the penetrability of apremilast into and across the nail plate, folloby the preparation of a novel nail lacquer formulation to improve its ungual and trans-ungual permeation for the treatment of nail psoriasis. Dexpanthenol and salicylic acid were found to be the …
-
Διερεύνηση της βέλτιστης θεραπευτικής προσέγγισης ανάμεσα στους αντι-TNFα, αντι-ΙL12/23, αντι-IL17 και αντι-IL23 βιολογικούς παράγοντες και την απρεμιλάστη σε ασθενείς με ψωρίαση σε δύσκολες-προς-αντιμετώπιση περιοχές και προσδιορισμός πιθανών προγνωστικών παραγόντων θεραπευτικής έκβασης
… infliximab, etanercept, certolizumab pegol or apremilast. The efficacy and safety of the respective treatments overall in psoriasis, and by anatomical region, were evaluated at weeks 16, 24, 52, 62 and 78. Statistical analysis was performed by analysis of covariance (ANCOVA), logistic …
-
Welches Medikament hat den schnellsten Wirkeintritt in der Behandlung von Psoriasis-Arthritis?
… 5mg (2,20 [1,41-2,99]); nach > 4 Wochen: Apremilast, Ustekinumab. Für TOA-ACR50 lagen alle Ergebnisse bei > 4 Wochen. Bezogen auf TOA-PASI75, zeigten gepoolte Ergebnisse einen Wirkeintritt nach < 3 Wochen für Therapien mit Ixekizumab und nach 6,03 Wochen [3,76-8,29] für Adalimumab. …
-
Διερεύνηση πιθανής ενθεσοπάθειας σε ασθενείς με ψωρίαση συγκεκριμένων εντοπίσεων, με σύγχρονες απεικονιστικές μεθόδους (High resolution MRI ή/και Ultrasound), πριν και μετά την αγωγή με βιολογικούς παράγοντες ή απρεμιλάστη
… with biological therapy " secukinumab" or apremilast. With the help of imaging techniques, the course and progress of the patients under treatment was monitored at 0 and 16 weeks. Method: The study included 76 patients of all ages who were followed at the outpatient clinics or in the …
-
Exploring co-milling as a strategy to improve the dissolution of poorly water-soluble drugs
… between low Tg (fenofibrate) and high Tg (apremilast) drugs. Apremilast, milled below its Tg, exhibited progressive amorphization and supersaturation during dissolution testing. A strong linear correlation between melting point depression and maximum drug concentration (cmax) in vitro (R2 > …
-
Photochemical 3D Printing of Bioresorbable Copolyesters for Applications in Transdermal Drug Delivery and Soft Tissue Repair
… than intravenous administration. Separately, apremilast-loaded, detachable MAPs were fabricated for sustained transdermal treatment of psoriasis. Detachable needles were designed to remain embedded in the skin after application, allowing for long-term drug release. Hollow MAPs were also …
-
Χαρακτηριστικά και αλλαγές θεραπείας ασθενών με Ψωριασική Αρθρίτιδα σε ένα κοινό δερματολογικό-ρευματολογικό ιατρείο
… και 10% στοχευμένους συνθετικούς παράγοντες( apremilast). Kατά την τελευταία εκτίμηση (μετά από μέση διάρκεια 15μηνών), μόνο 8% δεν λάμβανε καμία θεραπεία , 62% λάμβανε βιολογικούς παράγοντες, 46% μη-βιολογικούς παράγοντες και 10% στοχευμένους συνθετικούς παράγοντες. Σχετικά με την ενεργότητα …
-
Wirksamkeit und Sicherheit von systemischer Psoriasis-Therapie bei viraler Hepatitis, Diabetes mellitus oder Niereninsuffizienz. Systematische Reviews
… Studien unzureichend berichtet. In Studien zu Apremilast, Methotrexat (MTX) und TNF-Inhibitoren (TNFi) (geringe Patientenanzahl, unterschiedliche Studientypen mit hohem Verzerrungssrisiko) fanden sich keine Hinweise auf relevante Veränderungen von Nüchternglukose, HbA1c oder Insulinsensitivität …
-
Συσχέτιση δεικτών φλεγμονής με την εμφάνιση και την πορεία κατάθλιψης σε ψωριασικούς ασθενείς πριν και μετά τη χορήγηση συστηματικής αγωγής
… probably related to the use of ciclosporin and apremilast. As a result, these drugs should be administered with caution to patients with psoriasis and depression. The evaluation of both CRP and ESR and their use to detect the presence of depression in patients with psoriasis can be an important …
-
Decifrando os mecanismos moleculares de teratogênese da talidomida : genética, embriologia e biologia de sistemas
… no presente estudo. Ensaios de exposição com apremilast, análogo anti-inflamatório da talidomida, e diclofenaco foram realizados em embriões de galinha. Não foram encontradas anomalias nos embriões, porém alta taxa de letalidade foi visualizada em altas doses. Ainda em embriões de galinha, …